The Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate

Size: px
Start display at page:

Download "The Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate"

Transcription

1 The Treatment of Postperfusion Bleeding Using wlminocaproic Acid, Cryoprecipitate, Fresh-Frozen Plasma, and Protamine Sulfate Cary J. Lambert, M.D., Alain J. Marengo-Rowe, M.D., James E. Leveson, Ph.D., Robert H. Green, M.D., J. Peter Thiele, M.D., Gerald F. Geisler, M.D., Maurice Adam, M.D., and Ben F. Mitchel, M.D. ABSTRACT The evaluation of excessive hemorrhage was carried out in 774 patients after cardiopulmonary bypass. Excessive hemorrhage was defined in any adult patient as chest tube drainage of more than 600 ml within the first eight hours after operation. Using the prothrombin time, partial thromboplastin time, fibrinogen level, and hi-f titer tests, it was possible to differentiate medical from surgical bleeding. Hyperfibrinolytic bleeding was the most frequently identifiable coagulation disorder and occurred in 159 patients (2O0/o). All these patients were successfully treated with Amicar (Eaminocaproic acid) alone, or with Amicar supplemented with cryoprecipitate or fresh-frozen plasma. Three patients (0.4%) were noted to have residual heparin and required additional protamine sulfate. Five patients (0.6%) had normal coagulation studies and required immediate reexploration. The overall blood consumption per patient was 2.1 units of packed cells. Whole blood and platelets were not used. The diagnosis and management of patients with excessive hemorrhage after cardiopulmonary bypass can be problematical. In general, more advanced hemorrhagic problems develop in these patients than in patients with classic or inherited bleeding disorders, and the diagnosis is more difficult to establish. Postperfusion hemorrhage presents a complex situation involving surgical as well as nonsurgical factors, and sometimes both. The need for reexploration has been high and often the cardiac surgeon has been confronted by untidy, general- From the Departments of Thoracic Surgery and Special Hematology, Baylor University Medical Center and Wadley Central Blood Bank, Dallas, TX. Presented at the Fifteenth Annual Meeting of The Society of Thoracic Surgeons, Jan 15-17, 1979, Phoenix, AZ. Address reprint requests to Dr. Marengo-Rowe, Special Hematology Department, Baylor University Medical Center, 3500 Gaston Ave, Dallas, TX ized oozing, which is both frustrating and difficult to control. In another report we [ll] define what could be regarded as normal blood loss after a bypass operation and correlate specific blood coagulation tests with excessive bleeding. Abnormal or excessive bleeding is defined as chest tube drainage exceeding 600 ml in an adult patient within the first eight hours after open-heart operation. Using a combination of the prothrombin time (PT), partial thromboplastin time (PTT), fibrinogen level, and tri-f titer (TFT), it was possible to categorize any hemorrhagic tendency into five distinctly treatable entities. These are as follows: (1) hyperfibrinolysis, compensated; (2) hyperfibrinolysis, uncompensated, with hypofibrinogenemia and other coagulation factor deficiencies; (3) unneutralized heparin or heparin rebound; (4) surgical bleeding, and (5) combinations of these. The purpose of this communication is to describe how each patient who bleeds excessively after bypass can be appropriately diagnosed and treated. Material and Methods A group of 774 consecutive patients undergoing cardiopulmonary bypass operation were surveyed. The operation was done by one or more of a group of five established, cardiovascular surgeons. No patient was included in the study until an experience of 250 patients had been accomplished. This was done in order to exclude conditions that might be attributable either to technical or to learning differences [7]. During cardiopulmonary bypass, a bloodless prime, a bubble oxygenator, and a roller pump at moderate to hypothermic levels were used, complemented by cooling with topical saline solution with or without hypothermic root cardioplegia. The pump prime consisted of two by Cary J. Lambert

2 441 Lambert et al: Treatment of Postperfusion Bleeding liters of lactated Ringer s solution to which 6,000 units of heparin were added E2-41. Systemic heparinization consisted of 300 units per kilogram of body weight initially, followed by a further 50 units per kilogram given every 30 minutes on bypass. Throughout the operation, heparin levels were monitored at 30-minute intervals and measured by an actual plasma heparin assay procedure [51. At the termination of bypass, heparin was neutralized with a dose of protamine sulfate equal to one or one and a half times that of the heparin level measured at the last assay. In the vast majority of patients, the amount of blood suctioned during operation was so small, less than 200 ml, that it was discarded. The routine utilization of a cell saver system could not be justified on a need or cost basis. However, any significant preperfusion or postperfusion hemorrhage resulting in the pooling of blood was recovered by cardiotomy suckers and returned to the oxygenating circuit. This blood was routinely filtered through one macropore and one micropore filter. On the completion of bypass, all the perfusate was returned to the patient if his hemodynamic state permitted. Any residual volume, usually 500 to 1,000 ml, that was not returned to the patient in the operating room was collected and usually given to the patient in the intensive care unit. Preoperatively, each patient s hemostatic function was evaluated clinically and by laboratory means. The laboratory tests included an examination of the peripheral smear; clot retraction; bleeding time (Ivy); the prothrombin time (PT) (Dade); the partial thromboplastin time (PTT) (Hyland); platelet count with platelet aggregation (Biodata) to adenosine diphosphate, collagen, ristocetin, thrombin, epinephrine; fibrinogen (Dade); tri-f titer (TFT) [8]; and fibrin(ogen) split products (FSP). With the exception of the bleeding time, the same laboratory tests were repeated immediately after the completion of operation and then as indicated by abnormal bleeding or abnormal test values. All blood samples for laboratory testing were collected either by a clean venipuncture stick or from indwelling lines after the first 20 ml was discarded. For coagulation studies other than clot retraction, FSP, and platelet counts, blood was drawn into plastic tubes containing the correct amount of 3.2% sodium citrate anticoagulant. All testing was performed within 30 minutes of blood collection. Blood loss, as estimated by the volume of chest tube drainage, was measured at hourly intervals after operation until no more occurred. Then the chest tubes were removed. At all times only blood components were used for treatment [lo, 161. These components included packed red cells, cryoprecipitate and fresh-frozen plasma. Whole blood, fresh blood, platelet-rich plasma, and platelet concentrates were not used. Results Of the 774 patients who underwent aortocoronary bypass, 167 (22%) bled more than 600 ml within the first eight hours after operation. Five of them had normal coagulation studies and required immediate reexploration. In each, a definitive bleeding point requiring surgical intervention was found. All the remaining 162 patients had coagulation abnormalities severe enough to give rise to excessive bleeding and were successfully treated medically. In these patients, excessive bleeding postoperatively was best correlated with a PTT greater than 45 seconds, a PT greater than 19 seconds, a fibrinogen level less than 225 mg per deciliter, and a TFT equal to or less than 1:32. These laboratory findings, which occurred singly or in combination, formed the basis for rational therapy. In this clinical study, 255 patients (33%) required no blood or blood components; 352 (46%) received only packed red cells; and 164 (21%) received Amicar with or without cryoprecipitate or fresh-frozen plasma. Three patients (0.4%) required additional protamine sulfate. Five patients (0.6%) required reexploration for surgical bleeding. The overall average of blood components used per patient for the entire series was as follows: packed red cells, 2.1 units; cryoprecipitate, 2.5 units; and freshfrozen plasma, less than 1 unit. Diagnosis and Treatment In the patient with excessive bleeding after perfusion, the coagulopathies induced by oper-

3 442 The Annals of Thoracic Surgery Vol 28 No 5 November 1979 Classification and Treatment of Patients with Excessive Postoperative Bleeding PT PTT Cause of > 19 > 45 Fibrinogen TFT Bleeding sec sec < 225 mg/dl 1:32 Treatment Compensated hyperfibrinolysis No No No Yes Amicar Uncompensated YeslNo Yes Yes Yes Amicar, cryo- hyperfibrinolysis precipitate, FFP Heparin YeslNo Yes No Heparin effect Protamine Surgical No No No No Reexploration PT = prothrombin time; PTI = partial thromboplastin time; TFT = tri-f titer; FFP = fresh-frozen plasma. ation were explainable on the basis of a hyperfibrinolytic syndrome or inadequate heparin neutralization after coming off bypass. In 159 patients, there was excessive hemorrhage because of hyperfibrinolytic activity. This coagulopathy was either fully compensated or uncompensated, giving rise to various coagulation factor deficiencies. All patients with hyperfibrinolytic bleeding were treated with Amicar alone or with Amicar supplemented by cryoprecipitate and fresh-frozen plasma. In this series, because of rigorous heparin monitoring, only 3 patients were noted to have residual circulating heparin after operation and required treatment with protamine sulfate. The classification and treatment of patients with excessive postoperative bleeding is outlined in the Table. The characteristics of the various coagulopathies are as follows. Compensated hyperfibrinolysis (fibrinolysis without coagulation factor deficiencies) was identified by a falling saline TFT, a normal PTT, a normal PT, and the absence of any heparin effect in the TFT. The fibrinogen level was greater than 225 mg per deciliter. In every instance, treatment consisted of an intravenously administered bolus of Amicar (10 gm) given over 5 minutes, supplemented by another 10 gm at the rate of 2 gm per hour. Uncompensated hyperfibrinolysis (fibrinolysis with coagulation factor deficiencies) was identified by a falling saline TFT, a PTT greater than 45 seconds, a PT less than 19 seconds, a fibrinogen less than 225 mg per deciliter, and the absence of any heparin effect in the TFT. Treatment consisted of the Amicar regi- men as for compensated hyperfibrinolysis and the rapid infusion of 20 units of cryoprecipitate. However, if the PT was prolonged beyond 19 seconds, this regimen was supplemented with 4 units of fresh-frozen plasma. Unneutralized heparin was identified by the TFT by the lack of clot formation in the lower dilutions of the patient s plasma in saline and Amicar. The PTT and PT can also be prolonged, depending on the heparin concentration, but fibrinogen remains greater than 225 mg per deciliter. In these instances the patient was treated with an appropriate dose of protamine sulfate as determined by a heparin assay. In patients with a hemorrhagic diathesis associated with hyperfibrinolysis, compensated or uncompensated, the dose of Amicar is judged by the degree of fibrinolytic activity as determined by serial TFT, PTT, and PT. With an adequate urinary output (greater than 35 ml per hour), dosages up to 60 gm within the first hour were tolerated without adverse sequelae. Some bleeding patients with persistently prolonged PTTs required up to 40 units of cryoprecipitate within the first two hours. By contrast, patients with prolonged PTs have not required freshfrozen plasma in excess of the initial 4 units. Whenever coagulopathies occur, it is essential to implement treatment early and to pursue management aggressively until coagulation studies are normalized and hemorrhage stops. Comment Patients undergoing a cardiopulmonary bypass operation are classified as having an acceptable

4 443 Lambert et al: Treatment of Postperfusion Bleeding blood loss if chest tube drainage measures less than 600 ml within the first eight postoperative hours. In our series of 774 consecutive patients who underwent aortocoronary bypass, 607 (78%) fell within this range of normality and 167 (22%) demonstrated excessive blood loss. Of the patients who bled excessively, 5 (0.6%) had normal coagulation studies and required immediate reexploration. The remaining 162 (21%) patients with excessive hemorrhage had abnormal coagulation studies due to hyperfibrinolytic activity or unneutralized heparin, and all were treated medically. No correlation was found to exist between excessive bleeding and time on bypass or volume of suctioned blood. The most useful laboratory tests for hemostatic dysfunction were found to be a PTT greater than 45 seconds, a PT greater than 19 seconds, a fibrinogen less than 225 mg per deciliter, and a TFT equal to or less than 1 : 32. Platelet counts and function studies, as well as FSP estimations, bear no relevance to the clinical state and were not found to be of value. Hyperfibrinolytic bleeding was the most frequently identifiable coagulation disorder and was diagnosed in 159 (20%) patients. All were successfully treated with Amicar alone or with Amicar supplemented with cryoprecipitate and fresh-frozen plasma. Three patients (less than 1%) were noted to have residual heparin activity and were treated with protamine sulfate. Amicar or eaminocaproic acid is a 6 carbon monaminocarboxylic acid with a molecular weight of 143 daltons. The function of Amicar is inhibition of plasma plasminogen activator substances. Consequently, plasma plasminogen cannot be activated and fibrinolysis is inhibited [l, 61. Antifibrinolytic agents, such as Amicar, cannot prevent bleeding unless clotting can occur in the first place. The pharmacological effect of Amicar helps to arrest lysis of the protective blood clot, thus preventing hemorrhage. Amicar cannot be used successfully prophylactically because its action is very short-lived and, being a very small molecule, is rapidly excreted in the urine. In our study, Amicar in doses up to 90 gm within a two-hour period have been employed, without demonstrable ill effects, for ongoing hyperfibrinolytic activity associated with excessive hemorrhage. We did not encounter an increased incidence of blood coagulability or pulmonary embolism. The latter complication occurred in this study in 2 patients who had received 20 gm of Amicar each and in 4 patients who had not received Amicar. The absence of thromboembolic complications is in accord with the findings of other investigators [14, 151. Amicar also has been used successfully in the control of bleeding due to hyperfibrinolysis following transurethral resection [91, cardiac bypass operation in children with congenital heart disease 1121, and dental extractions in hemophiliacs [171, and in the prevention of early recurrence of spontaneous subarachnoid hemorrhage [13]. The poor reputation of Amicar in certain areas is due to its use in circumstances in which it should not have been employed. Only blood components, red cells, cryoprecipitate, and fresh-frozen plasma were used as treatment. Fresh blood, whole blood, and platelets were not needed. In this series 255 patients (33%) required no blood or blood components; 352 (46%) received only packed cells in order to correct persistent normovolemic anemia; and 164 (21%) received cryoprecipitate with or without fresh-frozen plasma to treat coagulopathies. The average of blood component used per patient was as follows: packed cells, 2.1 units; cryoprecipitate, 2.5 units; and fresh-frozen plasma, less than 1 unit. In this series of patients, no instance occurred in which excessive bleeding was caused by both surgical and hematological reasons. As the study has continued over the years, however, a few patients with this combination have been noted. In each instance, the blood coagulation profile was abnormal at the termination of operation, and the patient continued to bleed despite correction of the coagulation factors with appropriate therapy. In all bleeding situations, the value of rapid hematological assessment of the patient cannot be overemphasized. References 1. Ablondi FF, Hagan JJ, Phillips M, et al: Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by epsilonaminocaproic acid. Arch Biochem Biophys 82: 153, Beattie HW, Evans G, Garnet ES, et al: Albumin and water fluxes during cardiopulmonary bypass. J Thorac Cardiovasc Surg 67:926, 1974

5 444 The Annals of Thoracic Surgery Vol 28 No 5 November Brazier J, Cooper N, Maloney JF, et al: The adequacy of myocardial oxygen delivery and acute normovolemic anemia. Surgery 75:508, Cohen LH, Fosbert AM, Anderson WP, et al: The effects of phlebotomy, hemodilution and autologous transfusion on systemic oxygenation and whole blood utilization in open heart surgery. Chest 68:283, Dacie JV, Lewis SM: Practical Haematology. Fifth edition. Edinburgh and London, Churchilll Livingstone, 1975, p Griffin JD, Ellman L: Epsilon-aminocaproic acid (EACA). Semin Thromb Hemostas 5:27, Lambert CJ: Cardiopulmonary bypass hemorrhage: a surgeon s point of view. Semin Thromb Hemostas 3:90, Lambert CJ, Marengo-Rowe AJ, Leveson J, et al: The tri-f titer: a rapid test for estimation of plasma fibrinogen and detection of fibrinolysis, fibrin(ogen) split products, and heparin. Ann Thorac Surg 18:357, Madsen P, Strauch A: The effect of aminocaproic acid on bleeding following transurethral prostatectomy. J Urol 96:255, Marengo-Rowe AJ: The control of hemorrhage, in Human Hemostasis Prepared for the 28th Annual Meeting of the American Association of Blood Banks, Chicago, IL, Nov Edited by TS Zuck. Washington, DC, AABB Publications, 1975, p Marengo-Rowe AJ, Lambert CJ, Mitchel BF, et al: The evaluation of hemorrhage in cardiac patients who have undergone extracorporeal circulation. Transfusion 19:62, McClure PD, Izsak J: The use of epsilonaminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology 40:604, Nibbelink DW, Torner MS, Henderson WF: Intracranial aneurysms and subarachnoid hemorrhage: a cooperative study: antifibrinolytic therapy in recent onset subarachnoid hemorrhage. Stroke 6:622, Nilsson IM, Anderson L, Bjorkman SE: Epsilonaminocaproic acid (EACA) as a therapeutic agent based on 5 years clinical experience. Acta Med Scand [Suppll 448:5, Sengupta RP, Sing CS, Villarejo-Ortega FJ: Use of epsilon-aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysm. J Neurosurg 44:479, Shorr JB, Marx GF: New trends in intra-operative blood replacement. Anesth Analg (Cleve) 49546, Walsh PN, Rizza CR, Evans BR, et al: The therapeutic role of epsilon-aminocaproic acid (EACA) for dental extractions in hemophiliacs. Ann NY Acad Sci 20:267, 1975 Discussion DR. ROBERT s. LITWAK (New York, NY): I enjoyed the paper by Dr. Lambert and his colleagues. Their work is an interesting and helpful attempt to systematically analyze and treat the cause of postperfusion bleeding. But the problem, of course, is that one can never really be sure of a single cause of inappropriate bleeding, which-thanks to improved perfusion techniques-has become rather unusual. It is noteworthy that in this series, the decision to reexplore patients with excessive bleeding was based on the prior determination that the coagulation studies were all normal. Certainly, there can be no disagreement that prompt operative reentry is indicated in this subgroup. But is the converse true? That is, is it appropriate to defer early reexploration of a bleeding patient just because he has an abnormal coagulation pattern? We believe that there is far greater danger in delaying reexploration of any patient who is bleeding. It is entirely possible for surgical hemostasis to be imperfect in a patient who also happens to have a deranged coagulation spectrum. Indeed, it seems to me that we must assume the probability of inadequate surgical hemostasis in any patient who is bleeding actively after open intracardiac operation. What is the danger of early reexploration? In our experience the risk has been virtually nil. This was not the case, however, in early years when we delayed reentry because of an abnormal coagulation pattern in the patient who was bleeding after perfusion and who was being treated with blood replacement, various coagulation factors, and plasminogen activator inhibitors (such as eaminocaproic acid). Even if a patient with a coagulation abnormality is managed nonoperatively with apparent success and finally stops bleeding, the potential for tamponaderelated reduced cardiac performance is heightened because of retained intrapericardial clots. In summary, the nice study of Dr. Lambert and his colleagues is a useful contribution to our understanding of the nature of postperfusion bleeding. But experience dictates a clear message: regardless of the coagulation spectrum, if a patient is bleeding actively, assume a surgical hemostatic problem and reexplore early. DR. LAMBERT: I appreciate Dr. Litwak s remarks. I have had considerable experience with reexploring patients, and I do not believe that the inability to make a diagnosis and provide effective treatment is a justification to continue operating. Besides, if there is a hemostatic deficiency, operative intervention will provide no real benefit. Instead, the problem of bleeding will remain. I do not mean to imply that a patient should be allowed to die. He must be made hemodynamically stable, and we practice this program. No one in our series died because of bleeding.

Coagulation Defects and Bleeding in Open-Heart Surgery

Coagulation Defects and Bleeding in Open-Heart Surgery Coagulation Defects and Bleeding in Open-Heart Surgery Enrique E. Signori, M.D., John A. Penner, M.D., and Donald R. Kahn, M.D. H emorrhagic diathesis associated with extracorporeal circulation has been

More information

Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery

Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Butler Journal of Undergraduate Research Volume 2 Article 24 2016 Comparison of Tranexamic Acid and Aminocaproic Acid in Coronary Bypass Surgery Lisa K. LeCleir Butler University, lisa.lecleir@gmail.com

More information

How can ROTEM testing help you in cardiac surgery?

How can ROTEM testing help you in cardiac surgery? How can ROTEM testing help you in cardiac surgery? Complicated bleeding situations can appear intra and post operatively. They can be life-threatening and always require immediate action. A fast differential

More information

ADMINISTRATIVE CLINICAL Page 1 of 6

ADMINISTRATIVE CLINICAL Page 1 of 6 ADMINISTRATIVE CLINICAL Page 1 of 6 Anticoagulant Guidelines #2: REVERSAL OF OR MANAGEMENT OF BLEEDING WITH ANTICOAGULANTS Origination Date: Revision Date: Reviewed Date: 09/12 09/12, 01/13, 11/13, 11/15

More information

ECMO vs. CPB for Intraoperative Support: How do you Choose?

ECMO vs. CPB for Intraoperative Support: How do you Choose? ECMO vs. CPB for Intraoperative Support: How do you Choose? Shaf Keshavjee MD MSc FRCSC FACS Director, Toronto Lung Transplant Program Surgeon-in-Chief, University Health Network James Wallace McCutcheon

More information

MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE

MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE MASSIVE TRANSFUSION DR.K.HITESH KUMAR FINAL YEAR PG DEPT. OF TRANSFUSION MEDICINE CONTENTS Definition Indications Transfusion trigger Massive transfusion protocol Complications DEFINITION Massive transfusion:

More information

Serial Coagulation Studies in Patients Undergoing Mustard Procedure

Serial Coagulation Studies in Patients Undergoing Mustard Procedure Serial Coagulation Studies in Patients Undergoing Mustard Procedure Anne L. Wedemeyer, M.D., Aldo R. Castaiieda, M.D., J. Roger Edson, M.D., and William Krivit, M.D. ABSTRACT Following the Mustard procedure

More information

Cardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center

Cardiothoracic Fellow Expectations Division of Cardiac Anesthesia, Beth Israel Deaconess Medical Center The fellowship in Cardiothoracic Anesthesia at the Beth Israel Deaconess Medical Center is intended to provide the foundation for a career as either an academic cardiothoracic anesthesiologist or clinical

More information

Intra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman

Intra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman Intra-operative Effects of Cardiac Surgery Influence on Post-operative care Richard A Perryman Intra-operative Effects of Cardiac Surgery Cardiopulmonary Bypass Hypothermia Cannulation events Myocardial

More information

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006

TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 TRANSFUSION GUIDELINES FOR CARDIOTHORACIC UNIT 2006 CTU blood product transfusion guidelines 2006 1 Summary of guidelines RED CELLS (10-15ml/kg) This applies to ward patients / icu patients who are stable.

More information

Thromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation

Thromboelastography Use in the Perioperative Transfusion Management of a Patient with Hemophilia A Undergoing Liver Transplantation Open Journal of Organ Transplant Surgery, 2013, 3, 13-17 http://dx.doi.org/10.4236/ojots.2013.31003 Published Online February 2013 (http://www.scirp.org/journal/ojots) Thromboelastography Use in the Perioperative

More information

When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist

When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist When Should I Use Tranexamic Acid for Children? Dr Andrea Kelleher Consultant Adult and Paediatric Cardiac Anaesthetist When? When a drug is licenced for (the proposed) use When its use is supported by

More information

TRANSFUSIONS FIRST, DO NO HARM

TRANSFUSIONS FIRST, DO NO HARM TRANSFUSIONS FIRST, DO NO HARM BECAUSE BLOOD CAN KILL 7 TRALI DEATHS SINCE 2002 WMC 5 women BECAUSE In OB you are transfusing 2 instead of 1 BECAUSE BLOOD IS A LIQUID TRANSPLANT RISKS versus BENEFITS versus

More information

Requirement in Coronary Bypass Surgery

Requirement in Coronary Bypass Surgery Blood Loss and Bank Blood Requirement in Coronary Bypass Surgery Thomas Yeh, Jr., Larry Shelton, C.C.P., and Thomas J. Yeh, M.D. ABSTRACT With the use of nonblood prime and refinement in perfusion and

More information

Blood Transfusion Guidelines in Clinical Practice

Blood Transfusion Guidelines in Clinical Practice Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi

More information

Hemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands

Hemostasis and thrombosis in patients with liver disease. Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Hemostasis and thrombosis in patients with liver disease Ton Lisman, Dept Surgery, UMC Groningen, The Netherlands Importance of the liver in hemostasis Synthesis of Coagulation factors Fibrinolytic proteins

More information

EMSS17: Bleeding patients course material

EMSS17: Bleeding patients course material EMSS17: Bleeding patients course material Introduction During the bleeding patients workshop at the Emergency Medicine Summer School 2017 (EMSS17) you will learn how to assess and treat bleeding patients

More information

Intraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL

Intraoperative haemorrhage and haemostasis. Dr. med. Christian Quadri Capoclinica Anestesia, ORL Intraoperative haemorrhage and haemostasis Dr. med. Christian Quadri Capoclinica Anestesia, ORL Haemostasis is like love. Everybody talks about it, nobody understands it. JH Levy 2000 Intraoperative Haemorrhage

More information

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS

GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.

More information

Unrestricted. Dr ppooransari fellowship of perenatalogy

Unrestricted. Dr ppooransari fellowship of perenatalogy Unrestricted Dr ppooransari fellowship of perenatalogy Assessment of severity of hemorrhage Significant drops in blood pressure are generally not manifested until substantial bleeding has occurred, and

More information

the bleeding won t stop? Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital

the bleeding won t stop? Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital What do you do when the bleeding won t stop? Teddie Tanguay RN, MN, NP, CNCC(c) Teddie Tanguay RN, MN, NP, CNCC(c) Liane Manz RN, BScN, CNCC(c) Royal Alexandra Hospital Outline Case study Normal coagulation

More information

Shock and Resuscitation: Part II. Patrick M Reilly MD FACS Professor of Surgery

Shock and Resuscitation: Part II. Patrick M Reilly MD FACS Professor of Surgery Shock and Resuscitation: Part II Patrick M Reilly MD FACS Professor of Surgery Trauma Patient 1823 / 18 Police Dropoff Torso GSW Lower Midline / Right Buttock Shock This Monday Trauma Patient 1823 / 18

More information

Massive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad

Massive transfusion: Recent advances, guidelines & strategies. Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad Massive transfusion: Recent advances, guidelines & strategies Dr.A.Surekha Devi Head, Dept. of Transfusion Medicine Global Hospital Hyderabad Massive Hemorrhage Introduction Hemorrhage is a major cause

More information

Modern Transfusion Management in Cardiovascular Surgery

Modern Transfusion Management in Cardiovascular Surgery Modern Transfusion Management in Cardiovascular Surgery Linda Shore-Lesserson, M.D. Professor of Anesthesiology Albert Einstein School of Medicine Montefiore Medical Center Bronx, New York Patient Blood

More information

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate

Approach to bleeding disorders &treatment. by RAJESH.N General medicine post graduate Approach to bleeding disorders &treatment by RAJESH.N General medicine post graduate 2 Approach to a patient of bleeding diathesis 1. Clinical evaluation: History, Clinical features 2. Laboratory approach:

More information

Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms

Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms Use of epsilon aminocaproic acid (EACA) in the preoperative management of ruptured intracranial aneurysms RAM P. SENGUPTA, M.B., B.S., F.R.C.S., F.R.C.S.E., $1Nr C. So, M.B., B.S., F.R.A.C.S., AND FRANCISCO

More information

Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto

Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto Disclosures Relevant relationships with commercial entities: Octapharma, CSL Behring

More information

Bleeding, Coagulopathy, and Thrombosis in the Injured Patient

Bleeding, Coagulopathy, and Thrombosis in the Injured Patient Bleeding, Coagulopathy, and Thrombosis in the Injured Patient June 7, 2008 Kristan Staudenmayer, MD Trauma Fellow UCSF/SFGH Trauma deaths Sauaia A, et al. J Trauma. Feb 1995;38(2):185 Coagulopathy is Multi-factorial

More information

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban

Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting

More information

Effects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass

Effects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass Effects of Prostacyclin Infusion on Platelet Activation and Postoperative Blood Loss in Coronary Bypass Claes Aren, M.D., Kurt Feddersen, M.D., and Kjell Ridegran, M.D. ABSTRACT The effects of infusion

More information

Do Heparinase Thrombelastographs Predict Postoperative Bleeding?

Do Heparinase Thrombelastographs Predict Postoperative Bleeding? Original Article Do Heparinase Thrombelastographs Predict Postoperative Bleeding? Paulla Mashburn BS, Jodie Ecklund BS, CCP, Jeffrey Riley BA, CCT, CCP Program in Extracorporeal Circulation Technology,

More information

Increased postoperative blood loss after cardiac operations

Increased postoperative blood loss after cardiac operations Efficacy of Aprotinin, Epsilon Aminocaproic Acid, or Combination in Cyanotic Heart Disease Sandeep Chauhan, MD, Bisoi Akshay Kumar, MCh, Beeraka Heramba Rao, MD, Marigaddi Sanjeeva Rao, MCh, Bharat Dubey,

More information

Hydroxyethyl Starch versus Albumin in Cardiopulmonary Bypass Prime Solutions

Hydroxyethyl Starch versus Albumin in Cardiopulmonary Bypass Prime Solutions Hydroxyethyl Starch versus Albumin in Cardiopulmonary Prime Solutions Craig R. Saunders, M.D., Louis Carlisle, R.N., and Rodger L. Bick, M.D. ABSTRACT To compare hydroxyethyl starch (HES) with 25% albumin,

More information

Transfusion Requirements and Management in Trauma RACHEL JACK

Transfusion Requirements and Management in Trauma RACHEL JACK Transfusion Requirements and Management in Trauma RACHEL JACK Overview Haemostatic resuscitation Massive Transfusion Protocol Overview of NBA research guidelines Haemostatic resuscitation Permissive hypotension

More information

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature) 1 of 5 Policy #: 702 (PHL-702-05) Effective Date: 9/30/2004 Reviewed Date: 8/1/2016 Subject: TRANSFUSION GUIDELINES Approved by: Laboratory Director, Jerry Barker (electronic signature) Approved by: Laboratory

More information

GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE

GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE 2018 UPDATE QUICK SHEET 2018 American Heart Association GUIDELINES FOR THE EARLY MANAGEMENT OF PATIENTS WITH ACUTE ISCHEMIC STROKE A Summary for Healthcare Professionals from the American Heart Association/American

More information

Transfusion and Blood Conservation

Transfusion and Blood Conservation Transfusion and Blood Conservation Kenneth G. Shann, CCP Assistant Director, Perfusion Services Senior Advisor, Performance Improvement Department of Cardiovascular and Thoracic Surgery Montefiore Medical

More information

Major Haemorrhage Protocol. Commentary

Major Haemorrhage Protocol. Commentary Hairmyres Hospital Monklands Hospital Wishaw General Hospital Major Haemorrhage Protocol Commentary N.B. There is a separate NHSL protocol for the Management of Obstetric Haemorrhage Authors Dr Tracey

More information

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche Armando Tripodi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Dept. of Clinical Sciences and Community Health University

More information

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department

Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC) Dr. Klara Vezendi Szeged University Transfusiology Department Disseminated intravascular coagulation (DIC, consumptive coagulopathy) is a clinicopathologic

More information

A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion. Y. S. Nam, I. H. Kim, T. K. Yoon, C. N. Lee and K. Y.

A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion. Y. S. Nam, I. H. Kim, T. K. Yoon, C. N. Lee and K. Y. 12 1 A Case of Factor XII Deficiency Which was Found in Recurrent Spontaneous Abortion Y S Nam, I H Kim, T K Yoon, C N Lee and K Y Cha Department of Obstetrics and Gynecology, College of Medicine, Pocheon

More information

Appendix 3 PCC Warfarin Reversal

Appendix 3 PCC Warfarin Reversal Appendix 3 PCC Warfarin Reversal Reversal of Warfarin and Analogues 1. Principle of Procedure Guidelines for the Reversal of Oral-anticoagulation in the Event of Life Threatening Haemorrhage Prothrombin

More information

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS به نام خدا Disseminated Intravascular Coagulation M.Bahmanpour MD Assistant professor IUMS Algorithm for Diagnosis of DIC DIC Score factor score Presence of known underlying disorder No= 0 yes=2 Coagolation

More information

Approach to disseminated intravascular coagulation

Approach to disseminated intravascular coagulation Approach to disseminated intravascular coagulation Khaire Ananta Shankarrao 1, Anil Burley 2, Deshmukh 3 1.MD Scholar, [kayachikitsa] 2.Professor,MD kayachikitsa. 3.Professor and HOD,Kayachikitsa. CSMSS

More information

DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS

DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS The Role of Diagnostic Point-of-Care Testing Diagnostic testing is an essential component of Patient Blood Management. The accurate assessment of

More information

Going on Bypass. What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia

Going on Bypass. What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia Going on Bypass What happens before, during and after CPB. Perfusion Dept. Royal Children s Hospital Melbourne, Australia Circulation Brain Liver Kidneys Viscera Muscle Skin IVC, SVC Pump Lungs R.A. L.V.

More information

Coagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine

Coagulopathy: Measuring and Management. Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine Coagulopathy: Measuring and Management Nina A. Guzzetta, M.D. Children s Healthcare of Atlanta Emory University School of Medicine No Financial Disclosures Objectives Define coagulopathy of trauma Define

More information

Use of Prothrombin Complex Concentrates (PCC) CONTENTS

Use of Prothrombin Complex Concentrates (PCC) CONTENTS CONTENTS Page 1: Exclusion Criteria and Approved Indications for Use Page 2: Dosing / Administration / Storage Page 4: Prescribing / Monitoring / Dispensing Page 5: Cautions / Warnings / Cost Analysis

More information

Bleeding and Management of Coagulopathy

Bleeding and Management of Coagulopathy Bleeding and Management of Coagulopathy Jerrold H. Levy, MD, FAHA Professor of Anesthesiology Deputy Chair for Research Emory University School of Medicine Director, Cardiothoracic Anesthesiology CT Anesthesiology

More information

CONTROVERSIES IN LIVER TRANSPLANT COAGULATION MANAGEMENT

CONTROVERSIES IN LIVER TRANSPLANT COAGULATION MANAGEMENT Clinical Coagulation Monitoring in OLT 655 intraoperative hypothermia, goal-directed transfusion, and routine application of aprotinin the median blood loss in primary transplants in this series was 6Uofpacked

More information

A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta

A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta A cohort study of coagulation parameters and the use of blood products in surgery of the thoracic and thoracoabdominal aorta Claudio S. Cinà, MD, Spec Chir It, FRCSC, MSc, a Catherine M. Clase, MSc, FRCPC,

More information

2012, Görlinger Klaus

2012, Görlinger Klaus Gerinnungsmanagement der Gegenwart - wie gehen wir heute vor? 25. Allander Gerinnungsrunde am 15. März 2012 Klaus Görlinger Universitätsklinikum Essen klaus@goerlinger.net CSL Behring GmbH Octapharma AG

More information

Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD

Recombinant Activated Factor VII: Useful. Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Recombinant Activated Factor VII: Useful Department of Surgery Grand Rounds 11/8/10 David Mauchley MD Hemostasis and Coagulation Traditional cascade model Two convergent pathways Series of proteolytic

More information

Massive Transfusion. MPQC Spring Summit April 29, Roger Belizaire MD PhD

Massive Transfusion. MPQC Spring Summit April 29, Roger Belizaire MD PhD Massive Transfusion MPQC Spring Summit April 29, 2015 Roger Belizaire MD PhD Take home points 1. Blood is always available. Requests for massive transfusion or emergency release typically only require

More information

M B Garvey. University of Toronto

M B Garvey. University of Toronto Do I really need that test??? M B Garvey Professor Emeritus University of Toronto St Michael s Hospital No relevant conflicts of interest 1 HEMOSTASIS IS LIKE LOVE Everybody talks about it, nobody understands

More information

CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin

CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used

More information

Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference

Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference Use of Prothrombin Complex Concentrate to Reverse Coagulopathy Rio Grande Trauma Conference John A. Aucar, MD, MSHI, FACS, CPE EmCare Acute Care Surgery Del Sol Medical Center Associate Professor, University

More information

CVICU EXAM. Mrs. Jennings is a 71-year-old post-op CABG x5 with an IABP in her left femoral artery

CVICU EXAM. Mrs. Jennings is a 71-year-old post-op CABG x5 with an IABP in her left femoral artery CVICU EXAM 1111 North 3rd Street Mrs. Jennings is a 71-year-old post-op CABG x5 with an IABP in her left femoral artery 1. Nursing standards for a patient on an IABP device include: a. Know results of

More information

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION

EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION EDUCATIONAL COMMENTARY DISSEMINATED INTRAVASCULAR COAGULATION Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE

More information

Intraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding

Intraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding Intraoperative Autologous Blood Donation Preserves Red Cell Mass But Does Not Decrease Postoperative Bleeding Robert E. Helm, MD, John D. Klemperer, MD, Todd K. Rosengart, MD, Jeffrey P. Gold, MD, Powers

More information

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.

LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO. LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual

More information

Pre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out?

Pre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out? Pre-hospital Administration of Blood Products (PHBP) and Tranexamic acid (TXA): Is the Jury Still Out? Jessica K. Reynolds, MD Assistant Professor of Surgery University of Kentucky, Department of Trauma

More information

Transfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service

Transfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Transfusion 2004: Current Practice Standards Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Massive Transfusion Protocol (MTP) When should it be activated? Massive bleeding i.e. loss of one blood

More information

Navigating the Dichotomies Between Literature and Your Clinical Practice

Navigating the Dichotomies Between Literature and Your Clinical Practice Navigating the Dichotomies Between Literature and Your Clinical Practice Robert Groom, CCP, FPP Cardiovascular Institute at Maine Medical Center Disclosures No relevant conflicts related to this presentation

More information

coagulation defect of paracetamol-induced hepatic necrosis

coagulation defect of paracetamol-induced hepatic necrosis Gut, 1974, 15, 89-93 A controlled trial of heparin therapy in the coagulation defect of paracetamol-induced hepatic necrosis B. G. GAZZARD, R. CLARK, V. BORIRAKCHANYAVAT, AND ROGER WILLIAMS From the Liver

More information

The increasing use of normothermic cardiopulmonary

The increasing use of normothermic cardiopulmonary A Prospective, Randomized Study of Cardiopulmonary Bypass Temperature and Blood Transfusion Paul E. Stensrud, MD, Gregory A. Nuttall, MD, Maria A. de Castro, MD, Martin D. Abel, MD, Mark H. Ereth, MD,

More information

TRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES

TRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES TRANSFUSION SUPPORT IN HEPATOBILIARY AND PANCREATIC SURGERIES Dr.K.C.Usha Professor & Head Dept: Of Transfusion Medicine & Director, Model Blood Bank Government Medical College Trivandrum,Kerala INTRODUCTION

More information

Cardiopulmonary Bypass in Cyanotic Patients. A Review of the Problems and Suggested Strategies

Cardiopulmonary Bypass in Cyanotic Patients. A Review of the Problems and Suggested Strategies Cardiopulmonary Bypass in Cyanotic Patients A Review of the Problems and Suggested Strategies Extra-ordinary Problems Encountered During C.P.B. for Cyanotic Heart Disease 1. Extra Dilutional Requirements

More information

TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage

TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage TEG-Directed Transfusion in Complex Cardiac Surgery: Impact on Blood Product Usage Kevin Fleming, CCP; Roberta E. Redfern, PhD; Rebekah L. March, MPH; Nathan Bobulski, CCP; Michael Kuehne, PhD, PA-C; John

More information

WELCOME. Evaluation Summary

WELCOME. Evaluation Summary WELCOME Evaluation Summary 489 delegates from 40 countries Delegate s specialty 239 respondents Delegate s professional activity 208 respondents Overall Evaluation This symposium was helpful for your clinical

More information

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary

Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in

More information

NEONATE FOR REPAIR OF DIAPHRAGMATIC HERNIA ON ECMO

NEONATE FOR REPAIR OF DIAPHRAGMATIC HERNIA ON ECMO NEONATE FOR REPAIR OF DIAPHRAGMATIC HERNIA ON ECMO OBJECTIVES James Lynch, MD Gregory Schears, MD Mayo Clinic College of Medicine Rochester, MN 1. Review common treatment strategies in patients with diaphragmatic

More information

Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery

Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery Recombinant Factor Seven Therapy for Postoperative Bleeding in Neonatal and Pediatric Cardiac Surgery Hemant S. Agarwal, MBBS, Jo E. Bennett, BS, Kevin B. Churchwell, FAAP, MD, Karla G. Christian, MD,

More information

Intraoperative Use of Epsilon Pratiti C et al 273

Intraoperative Use of Epsilon Pratiti C et al 273 Intraoperative Use of Epsilon Pratiti C et al 273 ORIGINAL ARTICLE Intraoperative Use of Epsilon Amino Caproic Acid and Tranexamic Acid in Surgeries Performed Under Cardiopulmonary Bypass: a Comparative

More information

BLEEDING DISORDERS Simple complement:

BLEEDING DISORDERS Simple complement: BLEEDING DISORDERS Simple complement: 1. Select the statement that describe the thrombocytopenia definition: A. Marked decrease of the Von Willebrandt factor B. Absence of antihemophilic factor A C. Disorder

More information

Alternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia

Alternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia The Journal of ExtraCorporeal Technology Alternative Anticoagulation during Cardiovascular Procedures in Pediatric Patients with Heparin-Induced Thrombocytopenia I. Ricardo Argueta-Morales, MD; Monica

More information

Clinical Evaluation of Priming Solutions for Pump Oxygenator Perfusion

Clinical Evaluation of Priming Solutions for Pump Oxygenator Perfusion .. Clinical Evaluation of Priming Solutions for Pump Oxygenator Perfusion William H. Lee, Jr., M.D., Joseph W. Rubin, M.D., and Mary P. Huggins, B.S. ABSTRACT Various hemodilution agents are now used routinely

More information

Complications of Thrombolysis

Complications of Thrombolysis Complications of Thrombolysis David H. Jang, M.D. Lewis S. Nelson, M.D. Case Summary: An 88 year-old man with a past medical history of hypertension and paroxysmal atrial fibrillation presented to the

More information

CCAS CPB Workshop Curriculum Outline Perfusion: What you might not know

CCAS CPB Workshop Curriculum Outline Perfusion: What you might not know CCAS CPB Workshop Curriculum Outline Perfusion: What you might not know Scott Lawson, CCP Carrie Striker, CCP Disclosure: Nothing to disclose Objectives: * Demonstrate how the cardiopulmonary bypass machine

More information

Intra-operative Echocardiography: When to Go Back on Pump

Intra-operative Echocardiography: When to Go Back on Pump Intra-operative Echocardiography: When to Go Back on Pump GREGORIO G. ROGELIO, MD., F.P.C.C. OUTLINE A. Indications for Intraoperative Echocardiography B. Role of Intraoperative Echocardiography C. Criteria

More information

Patient Blood Management. Marisa B. Marques, MD UAB Department of Pathology November 17, 2016

Patient Blood Management. Marisa B. Marques, MD UAB Department of Pathology November 17, 2016 Patient Blood Management Marisa B. Marques, MD UAB Department of Pathology November 17, 2016 Learning Objectives Upon completion of the session, the participant will: 1) Differentiate between the various

More information

Adequate hemostasis remains an important issue in

Adequate hemostasis remains an important issue in Fresh Frozen Plasma in the Pediatric Pump Prime: A Prospective, Randomized Trial Mary M. McCall, MSN, Mindy M. Blackwell, MS, Jonathan T. Smyre, MS, Joseph J. Sistino, MPA, Jeffrey R. Acsell, BS, B. Hugh

More information

Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism

Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Interventional procedure consultation document Ultrasound-enhanced, catheter-directed thrombolysis for pulmonary embolism A pulmonary embolism (PE) is

More information

Blood Components & Indications for Transfusion. Neda Kalhor

Blood Components & Indications for Transfusion. Neda Kalhor Blood Components & Indications for Transfusion Neda Kalhor Blood products Cellular Components: Red blood cells - Leukocyte-reduced RBCs - Washed RBCs - Irradiated RBCs Platelets - Random-donor platelets

More information

Blood Management of the Cardiac Patient in the Postoperative Period

Blood Management of the Cardiac Patient in the Postoperative Period Blood Management of the Cardiac Patient in the Postoperative Period Al Stammers, MSA, CCP, Eric Tesdahl, PhD Andy Stasko MS, CCP, RRT, Linda Mongero, BS, CCP, Sam Weinstein, MD, MBA Goal To examine the

More information

Hemostatic Resuscitation

Hemostatic Resuscitation Hemostatic Resuscitation 30 th David Miller Trauma Symposium Bill Beck, MD Assistant Professor of Surgery Trauma, Emergency General Surgery, Critical Care Disclosures None Again. Mac user. Why I Like Trauma?

More information

Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last

Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last Bassett Medical Center The Mary Imogene Bassett Hospital Clinical Laboratory Blood Bank Title: MTP 2016 Revision: 2.00 Created By: Admin, The Last Approved Time: 7/22/2016 12:44:54 PM Massive Transfusion

More information

The Value of Factor VIII Levels in Acquired Hypofibrinogenemia

The Value of Factor VIII Levels in Acquired Hypofibrinogenemia The Value of Factor VIII Levels in Acquired Hypofibrinogenemia JAMES J. CORRIGAN, JR., M.D., BOBBIE B. BENNETT, B.S., A BERNARD BUEFFEL, M.D. Section of Pediatric Hematology, Department of Pediatrics,

More information

Fresh and Citrated Whole-Blood Specimens Can Produce Different Thromboelastography Results in Patients on Extracorporeal Membrane Oxygenation

Fresh and Citrated Whole-Blood Specimens Can Produce Different Thromboelastography Results in Patients on Extracorporeal Membrane Oxygenation Fresh and Citrated Whole-Blood Specimens Can Produce Different Thromboelastography Results in Patients on Extracorporeal Membrane Oxygenation Elizabeth A. Gilman, MD, 1 Christopher D. Koch, 1 Paula J.

More information

What s in the Massive Transfusion Protocol (MTP) Package?

What s in the Massive Transfusion Protocol (MTP) Package? What s in the Massive Transfusion Protocol (MTP) Package? The Massive Transfusion Protocol Package is a set of documents intended to improve the coordination of a Massive Transfusion Protocol. The kit

More information

Thromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH

Thromboelastograph (TEG ) Utilization in Blood Management. Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH Thromboelastograph (TEG ) Utilization in Blood Management Tim Shrewsberry, BS, CCP Firelands Regional Medical Center, Sandusky, OH TEG Hemostasis System ROTEM Delta Whole blood Hemostasis Analyzer Personalized

More information

5/30/2013. I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow. Trauma = #1 cause of death persons <40 yo 1

5/30/2013. I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow. Trauma = #1 cause of death persons <40 yo 1 I have no conflicts of interest to disclose. Alicia Privette, MD Trauma & Critical Care Fellow Trauma = #1 cause of death persons

More information

Thrombolysis administration

Thrombolysis administration Thrombolysis administration Liz Mackey Stroke Nurse Practitioner Western Health Sunshine & Footscray Hospital, Melbourne Thanks ASNEN committee members Skye Coote, Acute Stroke Nurse, Eastern Health (slide

More information

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III REGULATION OF COAGULATION Introduction HEMOSTASIS/THROMBOSIS III Regulation of Coagulation/Disseminated Coagulation necessary for maintenance of vascular integrity Enough fibrinogen to clot all vessels

More information

Medical Management of Adult Congenital Heart Disease

Medical Management of Adult Congenital Heart Disease Medical Management of Adult Congenital Heart Disease 1. Erythrocytosis 2. Pulmonary Hemorrhage 3. The Thrombosis Dilemma 4. Non-Cardiac Surgery: a) The anesthesiologist b) Bilirubin kinetics c) Post operative

More information

A Guide To Safe Blood Transfusion Practice

A Guide To Safe Blood Transfusion Practice A Guide To Safe Blood Transfusion Practice Marie Browett, Pavlina Sharp, Fiona Waller, Hafiz Qureshi, Malcolm Chambers (on behalf of the UHL Blood Transfusion Team) A Guide To Safe Blood Transfusion Practice

More information

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION CLINICAL FELLOWSHIP PROGRAM IN COAGULATION The Department of Pathology and Laboratory Medicine University of Alberta, Faculty of Medicine and Dentistry and Alberta Health Services CLINICAL FELLOWSHIP IN

More information

The control patients had at least the combination of cardiovascular failure necessitating vasoactive

The control patients had at least the combination of cardiovascular failure necessitating vasoactive ELECTRONIC SUPPLEMENTARY MATERIAL Material and methods Patients The control patients had at least the combination of cardiovascular failure necessitating vasoactive medication, respiratory failure necessitating

More information

Study of correlation of changes in D-DIMER levels and coagulation profile with the development of coagulation disorders

Study of correlation of changes in D-DIMER levels and coagulation profile with the development of coagulation disorders Original article: Study of correlation of changes in D-DIMER levels and coagulation profile with the development of coagulation disorders 1 Dr Gurpreet Singh, 2 Dr Mahima Sharma, 3 Dr R K Chrungoo, 4 Dr.

More information

in In traoperative Heparin Reversal

in In traoperative Heparin Reversal Use of the Activated Coagulation Time in In traoperative Heparin Reversal for Cardiopulmonary Operations ' Kenneth L. Mattox, M.D., Gene A. Guinn, M.D., Pedro A. Rubio, M.D., and Arthur C. Beall, Jr.,

More information